Clinical trials
Hormones clinical trials
Below are recruiting hormones clinical trials, each written for real people, not researchers. We’re tracking 422 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07005154RecruitingPhase 2
Study of ASP5541 for metastatic prostate cancer
This study tests an experimental drug called ASP5541 for men with metastatic prostate cancer (either hormone-sensitive or castration-resistant). It aims to see if the drug can slow cancer growth and improve outcomes when added to standard hormone therapy.
Huntsville, AlabamaAges 18 years+ - NCT06957691RecruitingPhase 2
Fezolinetant for hot flashes in men on hormone therapy
This study tests a medication called fezolinetant to see if it reduces hot flashes in men undergoing hormone therapy for prostate cancer. If you experience frequent hot flashes, this treatment might help alleviate them.
Boston, MassachusettsAges 40 years+ - NCT06948214RecruitingPhase 3
LUM-201 for growth hormone deficiency in children
This trial tests a new medicine called LUM-201 for children who haven't grown enough because their bodies don't make enough growth hormone. It aims to help kids who haven't been treated before and are still at an early stage of puberty.
Birmingham, AlabamaAges 3–11 - NCT06832202RecruitingPhase 2
HLX22 plus Enhertu for HR+, HER2-low breast cancer
This trial tests a new drug, HLX22, combined with Enhertu (trastuzumab deruxtecan) for people with advanced breast cancer that is hormone receptor positive and HER2-low. The goal is to see if the combination works better than Enhertu alone.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06922318RecruitingPhase 2
Combined suppression of MYC for advanced prostate cancer
This trial tests a new combination of drugs (ZEN-3694 and enzalutamide) for men with advanced prostate cancer that has stopped responding to standard hormonal treatments. It aims to see if this combination can help slow or stop the cancer from growing.
Baltimore, MarylandAges 18 years+ - NCT06803589RecruitingEarly Phase 1
Growth hormone for hard-to-treat stomach paralysis
This study tests if growth hormone can help people with long-term stomach paralysis (gastroparesis) that hasn't improved with standard care. It looks at whether the treatment reduces symptoms like nausea and feeling full too quickly.
Phoenix, ArizonaAges 18–65 - NCT06760546RecruitingPhase 3
Testing setmelanotide for weight gain after brain injury
This trial tests a daily injection called setmelanotide to see if it can help people who have gained weight due to a brain injury or condition affecting the hypothalamus. It may help reduce hunger and support weight loss.
Birmingham, AlabamaAges 4 years+ - NCT06756932RecruitingPhase 1
Bcl-2 inhibitor combo for advanced HR+ breast cancer
This trial tests a new Bcl-2 inhibitor (BGB-21447) combined with other therapies for advanced HR+/HER2- breast cancer that has already been treated with hormone therapy and a CDK4/6 inhibitor. It aims to see if these combinations are safe and effective.
Iowa City, IowaAges 18 years+ - NCT06709040Enrolling by invitation
Long-term safety of somapacitan in children with growth hormone deficiency
This study is watching children who are already taking somapacitan (a growth hormone injection) to see if it is safe over a long time. It collects information about growth and any side effects.
Glasgow, ScotlandAges Up to 18 years - NCT06694506Recruiting
Health outcomes in adults with childhood growth hormone deficiency
This study follows adults who had growth hormone deficiency as children and are now part of a research registry. It aims to understand their health outcomes as they transition into adulthood.
Brussels, Woluwe-saint-lambertAges 18 years+ - NCT06661122Recruiting
Darolutamide with ADT and docetaxel for low-volume metastatic prostate cancer
This study looks at how safe and effective the combination of darolutamide (a tablet), hormone therapy (ADT), and chemotherapy (docetaxel) is for Japanese men with prostate cancer that has spread in a limited way (low volume). It observes people in regular medical care, not in a research setting.
Multiple LocationsAges 18 years+ - NCT06629272Recruiting
Reducing Unnecessary Thyroid Hormone in Older Adults
This study is testing whether it’s safe to slowly reduce or stop thyroid hormone medication in older adults who may not need it. The goal is to improve health and avoid unnecessary treatment.
San Francisco, CaliforniaAges 65 years+ - NCT06307990Recruiting
Understanding thyroid hormone response problems
This trial is for people who may have a problem with how their body responds to thyroid hormone. It aims to better understand, diagnose, and monitor these conditions to improve care.
MilanAges Any age - NCT06037473Recruiting
PEG growth hormone for short stature in children
This trial tests if a long-acting growth hormone (PEGylated GH) helps children with various causes of short stature grow taller. It may be an option if your child has a condition like growth hormone deficiency, Turner syndrome, or idiopathic short stature.
Beijing, Beijing MunicipalityAges Up to 18 years - NCT06518837RecruitingPhase 2
Tirzepatide for weight loss in early breast cancer
This study tests if tirzepatide (a weight loss drug) can help women and men with early-stage hormone receptor-positive breast cancer who are overweight or obese. The goal is to see if losing weight can improve outcomes after completing their initial breast cancer treatment.
Elizabeth, New JerseyAges 18 years+ - NCT06531499RecruitingPhase 1
Study of a radioactive drug for advanced prostate cancer
This trial tests an extended treatment with a radioactive drug (177Lu-PSMA-617) to see how the body handles it, how safe it is, and how well it works. It is for men with metastatic castration-resistant prostate cancer who have not had chemotherapy yet.
Los Angeles, CaliforniaAges 18–100 - NCT06382948RecruitingPhase 3
Elacestrant and everolimus for ESR1-mutant advanced breast cancer
This trial tests a new combination of two oral targeted therapy pills (elacestrant and everolimus) for people with a specific type of advanced breast cancer. It is for those whose cancer has an ESR1 mutation and has stopped responding to CDK4/6 inhibitors and hormone therapy.
InnsbruckAges 18 years+ - NCT06388122Recruiting
Blood test study for HR+ breast cancer treatment monitoring
This study looks at a blood test (DiviTum TKa) to see how well it measures treatment response in people with hormone receptor-positive (HR+) breast cancer that has spread. The test may help doctors know if a treatment is working.
Jacksonville, FloridaAges 18 years+ - NCT06374459RecruitingPhase 1/Phase 2
Zunsemetinib and capecitabine for breast cancer with bone spread
This trial tests a new drug called zunsemetinib combined with the chemotherapy capecitabine for people with hormone receptor-positive, HER2-negative breast cancer that has spread to the bones. The goal is to see if this combination can better control the cancer.
Westwood, KansasAges 18 years+ - NCT05746650Recruiting
Study to improve healing after knee muscle-tendon repair
This study looks at how to improve healing at the muscle-tendon connection after knee reconstruction surgery. You may be able to join if you’re otherwise healthy, within a certain body-size range, and not using medicines that could change muscle or tendon healing.
CopenhagenAges 18–35 - NCT06306612Recruiting
Surgery plus hormone therapy for advanced prostate cancer
This trial tests whether removing the prostate (surgery) plus standard hormone therapy and chemotherapy can help men whose prostate cancer has spread to many places in the body. It is for men who have not yet had treatment for their cancer.
Shanghai, Shanghai MunicipalityAges 18–85 - NCT06280560Recruiting
IVF hormones and womb lining health study
This study looks at how IVF hormone treatments affect the womb lining and whether they cause aging cells to build up. It may help doctors improve IVF success rates.
Valencia, ValenciaAges 18–45 - NCT06245681Recruiting
How Hormone Therapy Affects the Heart and Liver
This study looks at how cross-sex hormone treatment affects the heart and fat in the liver. It aims to help understand the safety of hormone therapy in transgender individuals.
Vienna, State of ViennaAges 18–99 - NCT06224673RecruitingPhase 2
Testing ARX788 for HER2-low advanced breast cancer
This trial tests a new drug, ARX788, for people with HER2-low breast cancer that has spread or cannot be removed by surgery. The goal is to see if ARX788 helps shrink or control the cancer.
San Francisco, CaliforniaAges 18 years+
Hear when a new Hormones trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for hormones?
- Yes. Clin2 currently lists 422 recruiting hormones studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a hormones trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a hormones trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.